SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549
____________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): ~~March~~April 1525, 2016 Microlin Bio, Inc. (Exact name of registrant as specified in its charter)

Delaware	000-55425	45-4507811
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

135 East 57th Street, 24th Floor New York, NY	10022
(Address of principal executive offices)	(Zip Code)
Registrant’s telephone number, including area code: (646) 406-6243

Registrant’s telephone number, including area code: (646) 406-6243

___________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ]	Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)

[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SECTION 84- ~~– OTHER~~Matters ~~EVENTS~~Related to Accountants and Financial Statements

Item 84.01 ~~Other~~Changes ~~Events~~in Registrant’s Certifying Accountant.

On ~~March~~April 1525, ~~2015~~2016, we ~~executed~~dismissed ~~a non-binding term sheet with Marina Biotech~~RBSM, ~~Inc.~~LLP (the “~~Marina~~Former Accountant”), anas ~~oligonucleotide~~our ~~therapeutics~~independent ~~company~~auditor. ~~with~~Also ~~broad~~on ~~drug~~April ~~discovery technologies providing the ability to develop proprietary single and double-stranded nucleic acid therapeutics including siRNAs~~25, ~~microRNA~~ ~~mimics~~2016, ~~antagomirs,~~our ~~and~~board ~~antisense compounds, including messengerRNA therapeutics. The term sheet proposes a transaction in which we would purchase substantially all~~ of ~~the~~directors ~~assets~~appointed ofLJ ~~Marina in exchange for approximately 6.7 million shares of our common~~Soldinger ~~stock~~Associates, ~~which~~LLC ~~shall~~(the ~~represent~~“New ~~25%~~Accountant”) ofas our ~~issued~~new ~~and~~independent ~~outstanding~~registered ~~stock~~public onaccounting ~~a fully diluted basis following the issuance of such shares~~firm. ~~In addition, we would pay approximately $1 million in cash in various installments.~~

~~Completion~~The ofFormer ~~the~~Accountant ~~proposed~~was ~~acquisition~~engaged ison ~~contingent~~January ~~upon~~6, ~~certain~~2016. ~~closing~~From ~~conditions,~~the ~~including~~time ~~customary~~of ~~due~~its ~~diligence~~engagement ~~considerations,~~through the ~~negotiation~~date of its dismissal on April 25, ~~execution~~2016, ~~and~~the ~~delivery~~Former Accountant did not render an audit report on any of the Company’s annual financial statements or a review report on any of the Company’s interim ~~definitive~~quarterly ~~asset~~financial ~~purchase~~statements. ~~agreement~~As reported in our Current Report on Form 8-K filed December 22, 2015, the ~~approval~~Former Accountant did render an audit report on the financial statements of ~~Marina’s~~our ~~stockholders~~accounting acquirer, Microlin Bio, Inc. for the fiscal years ended September 30, 2015 and ~~our~~September ~~completion~~30, of2014. aThe ~~financing~~Former Accountant’s audit reports on the financial statements of atour ~~least~~accounting acquirer $5for ~~million.~~our ~~There~~fiscal ~~can~~years beended September 30, 2015 and 2014, contained no ~~assurance~~adverse ~~that~~opinion anor ~~asset~~disclaimer ~~purchase~~of ~~agreement~~opinion, nor were they qualified or amodified ~~closing~~as ~~will~~to ~~occur~~uncertainty, ~~based~~audit onscope ~~satisfaction~~or accounting principles, with exception of ~~these~~uncertainty ~~conditions~~regarding our ability to continue as a going concern.

~~SIGNATURES~~During the Company’s fiscal years ended September 30, 2015 and 2014, the subsequent interim period thereto, and through April 25, 2016, there were no “disagreements” (as such term is defined in Item 304 of Regulation S-K) with the Former Accountant on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements if not resolved to the satisfaction of the Former Accountant would have caused them to make reference thereto in their reports on the financial statements for such periods.

~~Pursuant~~During tothe Company’s fiscal years ended September 30, 2015 and 2014, and through the ~~requirements~~interim ofperiods ended April _25, 2016, there were the ~~Securities~~following “reportable ~~Exchange~~events” ~~Act~~(as such term is defined in Item 304 of ~~1934~~Regulation S-K). As disclosed in Part II, Item 9A of the ~~registrant~~Company’s Form ~~has~~10-K ~~duly~~for ~~caused~~the ~~this~~former ~~report~~fiscal toyear beended ~~signed~~December on31, ~~its~~2014, ~~behalf~~the byCompany’s management determined that the ~~undersigned~~Company’s internal ~~hereunto~~controls ~~duly~~over ~~authorized.~~financial reporting were not effective as of the end of such period due to the existence of material weaknesses related to the following:

~~Microlin~~(i) ~~Bio,~~lack ~~Inc.~~of an audit committee;

~~/s/~~(ii) ~~Joseph~~lack ~~Hernandez~~of a majority of outside directors on our board of directors; and

~~Joseph~~(iii) ~~Hernandez Executive~~management ~~Chairman~~dominated by a single individual/small group without adequate compensating controls.

~~Date:~~These ~~March~~material ~~17,~~weaknesses ~~2016~~have not been remediated as of the date of this Current Report on Form 8-K.

2Other than as disclosed above, there were no reportable events during the Company’s fiscal years ended September 30, 2015 and 2014 and through the interim periods ended April 25, 2016. We authorized the Former Accountant to respond fully and without limitation to all requests of the New Accountant concerning all matters related to the audited period by the Former Accountant, including with respect to the subject matter of each reportable event.

Prior to retaining the New Accountant, we did not consult with the New Accountant regarding either: (i) the application of accounting principles to a specified transaction, either contemplated or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements; or (ii) any matter that was the subject of a “disagreement” or a “reportable event” (as those terms are defined in Item 304 of Regulation S-K).

On April 25, 2016, the Company provided the Former Accountant with its disclosures in this Current Report on Form 8-K disclosing the dismissal of the Former Accountant and requested in writing that the Former Accountant furnish us with a letter addressed to the Securities and Exchange Commission stating whether or not they agree with such disclosures. The Former Accountant’s response is filed as an exhibit to this Current Report on Form 8-K.

SECTION 9 – Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

Exhibit No.	Description
16.1	Letter from RBSM, LLP to the Securities and Exchange Commission

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Microlin Bio, Inc.

/s/ Joseph Hernandez

Joseph Hernandez
Executive Chairman

Date: April 26, 2016

Filing Compare · Microlin Bio, Inc